Ptc Therapeutics (PTCT) Debt to Equity: 2012-2025
Historic Debt to Equity for Ptc Therapeutics (PTCT) over the last 11 years, with Sep 2025 value amounting to -$1.84.
- Ptc Therapeutics' Debt to Equity fell 257.12% to -$1.84 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.84, marking a year-over-year decrease of 257.12%. This contributed to the annual value of -$0.49 for FY2024, which is 15.38% up from last year.
- Per Ptc Therapeutics' latest filing, its Debt to Equity stood at -$1.84 for Q3 2025, which was up 30.72% from -$2.65 recorded in Q2 2025.
- In the past 5 years, Ptc Therapeutics' Debt to Equity ranged from a high of $300.02 in Q4 2021 and a low of -$4.77 during Q1 2022.
- For the 3-year period, Ptc Therapeutics' Debt to Equity averaged around -$1.25, with its median value being -$1.01 (2023).
- Its Debt to Equity has fluctuated over the past 5 years, first spiked by 43,697.70% in 2021, then tumbled by 402.23% in 2025.
- Ptc Therapeutics' Debt to Equity (Quarterly) stood at $300.02 in 2021, then tumbled by 100.62% to -$1.86 in 2022, then spiked by 68.49% to -$0.58 in 2023, then rose by 15.38% to -$0.49 in 2024, then tumbled by 257.12% to -$1.84 in 2025.
- Its last three reported values are -$1.84 in Q3 2025, -$2.65 for Q2 2025, and -$2.87 during Q1 2025.